tetano
Editor, Senior Moderator
IUBMB Life
. 2021 Jul 27.
doi: 10.1002/iub.2536. Online ahead of print.
One-Year Mortality and Consequences of COVID-19 in Cancer Patients: a Cohort Study
Chen Chai[SUP] #[/SUP][SUP] 1 [/SUP], Xiaojun Feng[SUP] #[/SUP][SUP] 2 [/SUP], Meixia Lu[SUP] #[/SUP][SUP] 3 [/SUP], Shoupeng Li[SUP] #[/SUP][SUP] 1 [/SUP], Kui Chen[SUP] #[/SUP][SUP] 4 [/SUP], Hongxiang Wang[SUP] #[/SUP][SUP] 5 [/SUP], Wendan Wang[SUP] 1 [/SUP], Zhaoming Tang[SUP] 6 [/SUP], Gang Cheng[SUP] 7 [/SUP], Xiaoxiong Wu[SUP] 1 [/SUP], Yunfeng Li[SUP] 1 [/SUP], Yuying Wen[SUP] 1 [/SUP], Banghong Da[SUP] 1 [/SUP], Hong Fan[SUP] 1 [/SUP], Lei Wang[SUP] 1 [/SUP], Fen Ai[SUP] 8 [/SUP], Wei Li[SUP] 8 [/SUP], Cao Peng[SUP] 1 [/SUP], Hongrong Zhang[SUP] 1 [/SUP], Shuang Wen[SUP] 1 [/SUP], Jinnong Zhang[SUP] 1 [/SUP], Yuxiong Weng[SUP] 9 [/SUP], Zehai Tang[SUP] 1 [/SUP]
Affiliations
Abstract
The one-year mortality and health consequences of COVID-19 in cancer patients are relatively underexplored. In this multicenter cohort study, 166 COVID-19 patients with cancer were compared with 498 non-cancer COVID-19 patients and 498 non-COVID cancer patients. The one-year all-cause mortality and hospital mortality rates in Cancer COVID-19 Cohort (30% and 20%) were significantly higher than those in COVID-19 Cohort (9% and 8%, both P<0.001) and Cancer Cohort (16% and 2%, both P<0.001). The 12-month all-cause post-discharge mortality rate in survival discharged Cancer COVID-19 Cohort (8%) was higher than that in COVID-19 Cohort (0.4%, P<0.001) but similar to that in Cancer Cohort (15%, P=0.084). The incidence of sequelae in Cancer COVID-19 Cohort (23%, 26/114) is similar to that in COVID-19 Cohort (30%, 130/432, P=0.13). The 1-year all-cause mortality was high among patients with hematologic malignancies (59%), followed by those who have nasopharyngeal, brain, and skin tumors (45%), digestive system neoplasm (40%), and lung cancers (28%). The rate was moderate among patients with genitourinary (13.6%), female genital (12.5%), breast (10.5%), and thyroid tumors (0). COVID-19 patients with cancer showed a high rate of in-hospital mortality and 1-year all-cause mortality, but the 12-month all-cause post-discharge mortality rate in survival discharged cancer COVID-19 patients was similar to that in Cancer Cohort. Comparing to COVID-19 Cohort, risk stratification showed that hematologic, nasopharyngeal, brain, digestive system, and lung tumors were high risk (44% vs 9%, P<0.001), while genitourinary, female genital, breast, and thyroid tumors had moderate risk (10% vs 9%, P=0.85) in COVID-19 Cancer Cohort. Different tumor subtypes had different effects on COVID-19. But if cancer patients with COVID-19 manage to survive their COVID-19 infections, then long-term mortality appears to be similar to the cancer patients without COVID-19, and their long-term clinical sequelae were similar to the COVID-19 patients without cancer.
Keywords: Cancer; Consequences; Coronavirus disease 2019; Mortality; Risk factors.
. 2021 Jul 27.
doi: 10.1002/iub.2536. Online ahead of print.
One-Year Mortality and Consequences of COVID-19 in Cancer Patients: a Cohort Study
Chen Chai[SUP] #[/SUP][SUP] 1 [/SUP], Xiaojun Feng[SUP] #[/SUP][SUP] 2 [/SUP], Meixia Lu[SUP] #[/SUP][SUP] 3 [/SUP], Shoupeng Li[SUP] #[/SUP][SUP] 1 [/SUP], Kui Chen[SUP] #[/SUP][SUP] 4 [/SUP], Hongxiang Wang[SUP] #[/SUP][SUP] 5 [/SUP], Wendan Wang[SUP] 1 [/SUP], Zhaoming Tang[SUP] 6 [/SUP], Gang Cheng[SUP] 7 [/SUP], Xiaoxiong Wu[SUP] 1 [/SUP], Yunfeng Li[SUP] 1 [/SUP], Yuying Wen[SUP] 1 [/SUP], Banghong Da[SUP] 1 [/SUP], Hong Fan[SUP] 1 [/SUP], Lei Wang[SUP] 1 [/SUP], Fen Ai[SUP] 8 [/SUP], Wei Li[SUP] 8 [/SUP], Cao Peng[SUP] 1 [/SUP], Hongrong Zhang[SUP] 1 [/SUP], Shuang Wen[SUP] 1 [/SUP], Jinnong Zhang[SUP] 1 [/SUP], Yuxiong Weng[SUP] 9 [/SUP], Zehai Tang[SUP] 1 [/SUP]
Affiliations
- PMID: 34318585
- DOI: 10.1002/iub.2536
Abstract
The one-year mortality and health consequences of COVID-19 in cancer patients are relatively underexplored. In this multicenter cohort study, 166 COVID-19 patients with cancer were compared with 498 non-cancer COVID-19 patients and 498 non-COVID cancer patients. The one-year all-cause mortality and hospital mortality rates in Cancer COVID-19 Cohort (30% and 20%) were significantly higher than those in COVID-19 Cohort (9% and 8%, both P<0.001) and Cancer Cohort (16% and 2%, both P<0.001). The 12-month all-cause post-discharge mortality rate in survival discharged Cancer COVID-19 Cohort (8%) was higher than that in COVID-19 Cohort (0.4%, P<0.001) but similar to that in Cancer Cohort (15%, P=0.084). The incidence of sequelae in Cancer COVID-19 Cohort (23%, 26/114) is similar to that in COVID-19 Cohort (30%, 130/432, P=0.13). The 1-year all-cause mortality was high among patients with hematologic malignancies (59%), followed by those who have nasopharyngeal, brain, and skin tumors (45%), digestive system neoplasm (40%), and lung cancers (28%). The rate was moderate among patients with genitourinary (13.6%), female genital (12.5%), breast (10.5%), and thyroid tumors (0). COVID-19 patients with cancer showed a high rate of in-hospital mortality and 1-year all-cause mortality, but the 12-month all-cause post-discharge mortality rate in survival discharged cancer COVID-19 patients was similar to that in Cancer Cohort. Comparing to COVID-19 Cohort, risk stratification showed that hematologic, nasopharyngeal, brain, digestive system, and lung tumors were high risk (44% vs 9%, P<0.001), while genitourinary, female genital, breast, and thyroid tumors had moderate risk (10% vs 9%, P=0.85) in COVID-19 Cancer Cohort. Different tumor subtypes had different effects on COVID-19. But if cancer patients with COVID-19 manage to survive their COVID-19 infections, then long-term mortality appears to be similar to the cancer patients without COVID-19, and their long-term clinical sequelae were similar to the COVID-19 patients without cancer.
Keywords: Cancer; Consequences; Coronavirus disease 2019; Mortality; Risk factors.